Greater Cannabis Company (GCAN) Common Equity (2016 - 2026)
Greater Cannabis Company's (GCAN) quarterly Common Equity came in at -$775025.0 in Q1 2026, up 5.94% year-on-year from -$731557.7 in Q1 2025, and down 4.5% quarter-over-quarter from -$741649.0 in Q4 2025.
Greater Cannabis Company (GCAN) Common Equity (2016 - 2026) Analysis & Trends
Greater Cannabis Company's Common Equity history runs 11 years deep, the most recent figure standing at -$775025.0 for Q1 2026.
- On a quarterly basis, Common Equity rose 5.94% year-over-year to -$775025.0 in Q1 2026; TTM through Mar 2026 was -$775025.0, a 5.94% increase from a year earlier, with the FY2025 full-year figure at -$741649.0, up 11.74% from the prior year.
- Common Equity retreated to -$775025.0 in Q1 2026 per GCAN's latest filing, from -$741649.0 in the prior quarter.
- Across five years, Common Equity topped out at -$544830.0 in Q4 2022 and bottomed at -$1.1 million in Q3 2025.
- The 5-year median for Common Equity is -$705843.0 (2024), against an average of -$736008.6.
- Across the five-year window, Common Equity sank 642.21% in 2022 and rose 11.74% in 2025, its largest moves.
- Year by year, Common Equity stood at -$544830.0 in 2022, then retreated by 21.36% to -$661232.0 in 2023, then declined by 27.08% to -$840273.0 in 2024, then rose by 11.74% to -$741649.0 in 2025, then retreated by 4.5% to -$775025.0 in 2026.
- Per Business Quant, the three latest GCAN Common Equity figures stand at -$775025.0 (Q1 2026), -$741649.0 (Q4 2025), and -$1.1 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.93 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 8.23 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 3.23 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 47.38 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 5.90 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 56.13 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.66 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 3.41 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.50 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | -775,025.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -775,025.00 |
| Dec 31, 2025 | -741,649.00 |
| Sep 30, 2025 | -1.11 Mn |
| Jun 30, 2025 | -1.07 Mn |
| Mar 31, 2025 | -823,984.00 |
| Dec 31, 2024 | -840,273.00 |
| Sep 30, 2024 | -796,925.00 |
| Jun 30, 2024 | -750,760.00 |
| Mar 31, 2024 | -705,843.00 |
| Dec 31, 2023 | -661,232.00 |
| Sep 30, 2023 | -650,371.00 |
| Jun 30, 2023 | -632,941.00 |
| Mar 31, 2023 | -587,898.00 |
| Dec 31, 2022 | -544,830.00 |
| Sep 30, 2022 | -561,429.00 |
| Jun 30, 2022 | -641,653.00 |
| Mar 31, 2022 | -616,748.00 |
| Dec 31, 2021 | -469,062.00 |
| Sep 30, 2021 | -272,731.00 |
| Jun 30, 2021 | -86,452.00 |